Document Detail


Dirithromycin in the treatment of streptococcal pharyngitis.
MedLine Citation:
PMID:  8478315     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A double-blind, double-dummy, randomized, multicentre study compared the safety and the efficacy of dirithromycin (two 250 mg tablets, once daily) to erythromycin base (four 250 mg tablets, four times daily) for ten days in the treatment of proven group A beta-haemolytic (GABHs) streptococcal pharyngitis. Five-hundred and fifty-three patients (265 dirithromycin, 288 erythromycin) were enrolled in the trial and analysed for efficacy and safety. Clinical and bacteriological evaluations were performed pre-therapy, during therapy (days 3-5), post-therapy (three to five days after completion of treatment), and late post-therapy (three to five weeks after treatment). All patients qualified for safety analysis. A negative pre-therapy culture was the predominant reason a patient did not qualify for analysis of efficacy. At post-therapy, favourable clinical responses (cure or improvement) were reported for 94.1% (159/169) of dirithromycin and 94.6% (158/167) of erythromycin patients who qualified for efficacy analysis. Post-therapy throat cultures were negative for GABH streptococci in 79.3% (134/169) of dirithromycin patients and 86.2% (144/167) of patients treated with erythromycin (P = 0.314). At late post-therapy 87.6% (134/153) of dirithromycin and 88.7% (134/151) of erythromycin patients reported a favourable clinical response; pathogens were absent in 69.9% (107/153) of dirithromycin and 86.1% (130/151) of erythromycin patients (P = 0.001). The adverse event profile of the two drugs was comparable although digestive and cutaneous adverse events were reported more frequently in the erythromycin treatment group. In this study, more dirithromycin patients had throat cultures positive for GABH streptococci at late post-therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
M Derriennic; P M Conforti; G D Sides
Related Documents :
3182455 - Efficacy of ofloxacin in the treatment of lower respiratory tract infections in general...
1951545 - Adjunctive clindamycin therapy for preterm labor: results of a double-blind, placebo-co...
12410215 - Enteral vancomycin to control methicillin-resistant staphylococcus aureus outbreak in m...
3895175 - Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of ...
15458995 - Effect of web-based depression literacy and cognitive-behavioural therapy interventions...
20332145 - Diethylstilbestrol exposure in utero and depression in women.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  31 Suppl C     ISSN:  0305-7453     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  1993 Mar 
Date Detail:
Created Date:  1993-05-27     Completed Date:  1993-05-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  89-95     Citation Subset:  IM    
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Saint Cloud, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Bacterial Agents
Double-Blind Method
Erythromycin / adverse effects,  analogs & derivatives*,  therapeutic use
Female
Humans
Macrolides
Male
Pharyngitis / drug therapy*,  microbiology
Streptococcal Infections / drug therapy*
Streptococcus pyogenes*
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Macrolides; 114-07-8/Erythromycin; 62013-04-1/dirithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tissue distribution of dirithromycin: comparison with erythromycin.
Next Document:  Clinical efficacy of dirithromycin in pharyngitis and tonsillitis.